The economic burden of neonatal abstinence syndrome in the United States

Addiction

Volumn 112, Issue 9, 2017, Pages 1590-1599

  Corr, Tammy E ^a   Hollenbeak, Christopher S ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Buprenorphine; finnegan scores; maternal substance abuse; methadone; neonatal abstinence syndrome; opioid abuse; prescription opioids; withdrawal

Indexed keywords

COST OF ILLNESS; ECONOMICS; FEMALE; HUMAN; LENGTH OF STAY; MALE; NEONATAL ABSTINENCE SYNDROME; NEWBORN; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

COST OF ILLNESS; FEMALE; HUMANS; INFANT, NEWBORN; LENGTH OF STAY; MALE; NEONATAL ABSTINENCE SYNDROME; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85020469538     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13842     Document Type: Article

References (36)

1. Finnegan L. P., Kron R. E., Connaughton J. F., Emich J. P. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm 1975; 12: 19–32.
2. Hudak M. L., Tan R. C. Neonatal drug withdrawal. Pediatrics 2012; 129: e540–60.
3. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134: e547–61.
4. Ailes E. C., Dawson A. L., Lind J. N., Gilboa S. M., Frey M. T., Broussard C. S. et al. Opioid prescription claims among women of reproductive age—United States, 2008–2012. Morb Mortal Wkly Rep 2015; 64: 37–41.
5. Patrick S. W., Schumacher R. E., Benneyworth B. D., Krans E. E., McAllister J. M., Davis M. M. Neonatal abstinence syndrome and associated health care expenditures. JAMA 2012; 307: 1934–1940.
6. Patrick S. W., Davis M. M., Lehmann C. U., Cooper W. O. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015; 35: 650–655.
7. Tolia V. N., Patrick S. W., Bennett M. M., Murthy K., Sousa J., Smith P. B. et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015; 372: 2118–2126.
8. O'Grady M. J., Hopewell J., White M. J. Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child Fetal Neonatal Ed 2009; 94: F249–52.
9. Healthcare Cost and Utilization Project (HCUP). Introduction to the HCUP KIDS' Inpatient Database (KID), 2012. Available at: https://www.hcup-us.ahrq.gov/db/nation/kid/kid_2012_introduction.jsp#table2 (accessed 17 August 2015) (Archived at http://www.webcitation.org/6q49JJ0zF on 28 April 2017).
10. Shwartz M., Young D. W., Siegrist R. The ratio of costs to charges: how good a basis for estimating costs? Inquiry 1995; 32: 476–481.
11. Leuven E., Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. 2003. Available at: http://ideas.repec.org/c/boc/bocode/s432001.html (accessed 17 August 2015) (Archived at http://www.webcitation.org/6q49JJ0zF on 28 April 2017).
12. Patrick S. W., Kaplan H. C., Passarella M., Davis M. M., Lorch S. A. Variation in treatment of neonatal abstinence syndrome in US Children's Hospitals, 2004–2011. J Perinatol 2014; 34: 867–872.
13. Norton E. C., Zarkin G. A., Calingaert B., Bradley C. J. The effect of maternal substance abuse on the cost of neonatal care. Inquiry 1996; 33: 247–257.
14. Kliff SKD. One hospital charges $8,000—another, $38,000. Washington Post 8 May 2013.
15. Young J., Kirkham C. Hospital prices no longer secret as new data reveals bewildering system, staggering cost differences. Huffington Post 8 May 2013.
16. Hamavid H., Birger M., Bulchis A. G., Lomsadze L., Joseph J., Baral R. et al. Assessing the complex and evolving relationship between charges and payments in US hospitals: 1996–2012. PLOS ONE 2016; 11: e0157912.
17. Pizzi L. T. L. J. Economic Evaluation in U.S. Health Care, Principles and Applications. Sudbury, MA: Jones and Bartlett Publishers, Inc.; 2006.
18. Finkler S. A. The distinction between cost and charges. Ann Intern Med 1982; 96: 102.
19. Warren M. D., Miller A. M., Traylor J., Bauer A., Patrick S. W. Implementation of a statewide surveillance system for neonatal abstinence syndrome—Tennessee, 2013. Morb Mortal Wkly Rep 2015; 64: 125–128.
20. Jones H. E., O'Grady K. E., Malfi D., Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17: 372–386.
21. Ebner N., Rohrmeister K., Winklbaur B., Baewert A., Jagsch R., Peternell A. et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007; 87: 131–138.
22. Asti L., Magers J. S., Keels E., Wispe J., McClead R. E. A quality improvement project to reduce length of stay for neonatal abstinence syndrome. Pediatrics 2015; 135: e1494–500.
23. Sarkar S., Donn S. M. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 2005; 26: 15–17.
24. Mehta A., Forbes K. D., Kuppala V. S. Neonatal abstinence syndrome management from prenatal counseling to postdischarge follow-up care: results of a national survey. Hospital Pediatr 2013; 3: 317–323.
25. Bagley S., Wachman E. M., Holland E., Brogly S. B. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract 2014; 9: 19.
26. Oji-Mmuo C. N., Michael E. J., McLatchy J., Lewis M. M., Becker J. E., Doheny K. K. Skin conductance at baseline and postheel lance reflects sympathetic activation in neonatal opiate withdrawal. Acta Paediatr 2015; 105: e99–106.
27. Clinical Trials.gov. Available at: https://clinicaltrials.gov/ct2/results?term=neonatal+abstinence+syndrome&Search=Search (accessed 4 April 2016) (Archived at http://www.webcitation.org/6q49mveQF on 28 April 2017).
28. Nayeri F., Sheikh M., Kalani M., Niknafs P., Shariat M., Dalili H. et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatr 2015; 15: 57.
29. Brown M. S., Hayes M. J., Thornton L. M. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol 2014; 35: 278–283.
30. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320–2331.
31. Saiki T., Lee S., Hannam S., Greenough A. Neonatal abstinence syndrome—postnatal ward versus neonatal unit management. Eur J Pediatr 2009; 169: 95–98.
32. Kelly L. E., Knoppert D., Roukema H., Rieder M. J., Koren G. Oral morphine weaning for neonatal abstinence syndrome at home compared with in-hospital: an observational cohort study. Pediatr Drugs 2014; 17: 151–157.
33. Lee J., Hulman S., Musci M., Stang E. Neonatal abstinence syndrome: influence of a combined inpatient/outpatient methadone treatment regimen on the average length of stay of a Medicaid NICU population. Popul Health Manag 2015; 18: 392–397.
34. Backes C. H., Backes C. R., Gardner D., Nankervis C. A., Giannone P. J., Cordero L. Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting. J Perinatol 2011; 32: 425–430.
35. Burns L., Mattick R. Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug Alcohol Rev 2007; 26: 487–492.
36. Hunt R. W., Tzioumi D., Collins E., Jeffery H. E. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008; 84: 29–35.